Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane

BioDrugs

Volumn 27, Issue 5, 2013, Pages 469-478

  Saji, Shigehira ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; CABAZITAXEL; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERIBULIN; ETIRINOTECAN PEGOL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HALICHONDRIN B; IRINOTECAN; IXABEPILONE; LAPATINIB; LAROTAXEL; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEMETREXED; PLX 3397; RAMUCIRUMAB; SORAFENIB; TAXANE DERIVATIVE; TESETAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; HUMAN; METASTASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FURANS; HUMANS; KETONES; TAXOIDS;

EID: 84885101825     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0038-1     Document Type: Review

References (54)

1. GLOBOCAN. GLOBOCAN breast cancer fact sheet. 2013. http://globocan.iarc. fr/factsheets/cancers/breast.asp. Accessed 16 Jan 2013.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
3. National Cancer Institute. SEER stat fact sheets: breast. http://seer.cancer.gov/statfacts/html/breast.html. Accessed 16 Jan 2013.
4. Morris PG. Advances in therapy: eribulin improves survival for metastatic breast cancer. Anti-cancer Drugs. 2010;21(10):885-9. doi: 10.1097/CAD. 0b013e32833ed62e.
5. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v15-9. doi: 10.1093/annonc/mdq160.
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): breast cancer. Version 3. 2012. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed 15 Jan 2013.
7. Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23(Suppl 6):vi46-51. doi: 10.1093/annonc/mds195.
8. Ayoub JP, Verma S, Verma S. Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr Oncol. 2012;19(2):91-105. doi: 10.3747/co.19.1024.
9. Saji S, Sato F, Ueno NT. Fuel, electricity, ER and HER2 - a hybrid-car model of breast cancer. Nat Rev Clin Oncol. 2012;9(7). doi: 10.1038/nrclinonc. 2012.9-c1.
10. Dufresne A, Pivot X, Tournigand C, Facchini T, Altweegg T, Chaigneau L, et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;107(2):275-9. doi: 10.1007/s10549-007-9550-7.
11. ® (capecitabine) tablets. Prescribing information. 2011. http://www.gene.com/download/pdf/xeloda-prescribing.pdf Accessed 16 Jan 2013.
12. ® (eribulin mesylate) injection. Prescribing information. 2012. http://www.halaven.com/sites/default/files/ HALAVEN-full-Prescribing-Information.pdf. Accessed 16 Jan 2013.
13. ® Kit (ixabepilone) for injection. 2011. http://packageinserts.bms.com/pi/pi-ixempra.pdf. Accessed 16 Jan 2013.
14. Aftimos P, Awada A. Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next? Adv Ther. 2011;28(11):973-85. doi: 10.1007/s12325-011-0070-9.
15. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086-95. doi: 10.1158/1535-7163.MCT-04-0345.
16. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49(6):1331-7. doi: 10.1021/bi901810u.
17. Ashley N, Poulton J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun. 2009;378(3):450-5. doi: 10.1016/j.bbrc.2008.11.059.
18. Eli Lilly and Co. Gemzar (gemcitabine for injection) powder, lyophilized, for solution for intravenous use. Prescribing information. http://pi.lilly.com/ us/gemzar.pdf. Accessed 1 Mar 2013.
19. Kuhn JG. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother. 2001;35(2):217-27.
20. Pasetto LM, D'Andrea MR, Brandes AA, Rossi E, Monfardini S. The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol. 2006;60(1):59-75. doi: 10.1016/j.critrevonc.2006.02.003.
21. Pfizer. Camptosar (irinotecan) injection, intravenous infusion. Prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=533. Accessed 1 Mar 2013.
22. US Food and Drug Administration. FDA approves new treatment option for late-stage breast cancer. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2010/ucm233863.htm. Accessed 1 Mar 2013.
23. Eisai. Halaven™ (eribulin) receives European Commission approval for advanced breast cancer. http://www.eisai.com/news/enews201125pdf.pdf. Accessed 1 Mar 2013.
24. Eisai. Halaven® receives approval in Japan for the treatment of inoperable and recurrent breast cancer. http://www.eisai.com/news/ enews201133pdf.pdf. Accessed 1 Mar 2013.
25. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009;15(12):4213-9. doi: 10.1158/1078-0432.CCR-09-0360.
26. Mukohara T, Nagai S, Mukai H, Namiki M, Minami H. Eribulin mesylate in patients with refractory cancers: a phase I study. Invest New Drugs. 2012;30(5):1926-33. doi: 10.1007/s10637-011-9741-2.
27. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27(18):2954-61. doi: 10.1200/JCO.2008.17.7618.
28. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467.
29. Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23(6):1441-8. doi: 10.1093/annonc/mdr444.
30. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6.
31. Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Wanders J, et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes [presentation S6-6]. In: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, 2012.
32. ® versus capecitabine in locally advanced or metastatic breast cancer presented at 2012 SABCS. http://www.eisai.com/news/news201281. html. Accessed 25 Feb 2013.
33. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009;15(12):4207-12. doi: 10.1158/1078-0432.CCR-08-2429.
34. ACORN Research. Phase I/II study of neoadjuvant carboplatin, eribulin mesylate and trastuzumab (ECH) for operable HER2 positive breast cancer [ClinicalTrials.gov identifier NCT01388647]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01388647. Accessed 29 Jan 2013.
35. Emory University, Eisai. Phase II neoadjuvant trial of eribulin followed by dose dense doxorubicin and cyclophosphamide for Her2-negative, locally advanced breast cancer [ClinicalTrials.gov identifier NCT01498588]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials. gov/ct2/show/NCT01498588. Accessed 29 Jan 2013.
36. M.D. Anderson Cancer Center, Eisai. A randomized phase II neoadjuvant study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in women with early stage breast cancer not overexpressing HER-2 [ClinicalTrials.gov identifier NCT01593020]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www. clinicaltrials.gov/ct2/show/NCT01593020. Accessed 29 Jan 2013.
37. Sarah Cannon Research Institute, Eisai. A randomized phase II study of eribulin/cyclophosphamide or docetaxel/cyclophosphamide as neoadjuvant therapy in locally advanced HER2-negative breast cancer [ClinicalTrials.gov identifier NCT01527487]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01527487. Accessed 29 Jan 2013.
38. Northwestern University, Eisai. Phase II neoadjuvant trial with carboplatin and eribulin mesylate in triple negative breast cancer patients [ClinicalTrials.gov identifier NCT01372579]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01372579. Accessed 29 Jan 2013.
39. Sarah Cannon Research Institute, Eisai. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy [ClinicalTrials.gov identifier NCT01401959]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www. clinicaltrials.gov/ct2/show/NCT01401959. Accessed 29 Jan 2013.
40. Eisai. A phase II, multicenter, single-arm, feasibility study of eribulin in combination with capecitabine for adjuvant treatment in estrogen receptor-positive early stage breast cancer [ClinicalTrials.gov identifier NCT01439282]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01439282. Accessed Jan 29 2013.
41. Eisai. A phase II, single-arm, feasibility study of dose dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate for the adjuvant treatment of early stage breast cancer [ClinicalTrials.gov identifier NCT01328249]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01328249. Accessed 29 Jan 2013.
42. Eisai. A phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor two (HER2) positive breast cancer [ClinicalTrials.gov identifier NCT01269346]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01269346. Accessed 29 2013.
43. German Breast Group. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with HER2-positive metastatic breast cancer (E-VITA) [ClinicalTrials.gov identifier NCT01534455]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01534455. Accessed 29 Jan 2013.
44. Eisai. A phase 2, multicenter, single-arm study of single-agent eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor two (HER2) negative breast cancer [ClinicalTrials.gov identifier NCT01268150]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01268150. Accessed 29 Jan 2013.
45. ImClone. An open-label, multicenter, randomized, phase 2 study evaluating the efficacy and safety of ramucirumab (IMC-1121B) drug product in combination with eribulin versus eribulin monotherapy in unresectable, locally-recurrent or metastatic breast cancer patients previously treated with anthracycline and taxane therapy [ClinicalTrials.gov identifier NCT01427933]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials. gov/ct2/show/NCT01427933. Accessed 29 Jan 2013.
46. Rugo H, Susan G. Komen Breast Cancer Foundation, Plexxikon, Eisai. Enhancing efficacy of chemotherapy in triple negative/basal-like breast cancer by targeting macrophages: a multicenter phase Ib/II study of PLX 3397 and eribulin in patients with metastatic breast cancer [ClinicalTrials.gov identifier NCT01596751]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01596751. Accessed 29 Jan 2013.
47. Eisai. A phase 1b/2, multicenter, randomized, open-label, dose-escalation and confirmation study of eribulin in combination with capecitabine [ClinicalTrials.gov identifier NCT01323530]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01323530. Accessed 29 Jan 2013.
48. University of California, San Francisco, Eisai Inc. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with solid tumor malignancies [ClinicalTrials.gov identifier NCT01554371]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/ NCT01554371. Accessed 29 Jan 2013.
49. Bayer. A phase 1, multi-center, non-randomized, open label, dose escalation design study of sorafenib (BAY43-9006) in combination with eribulin in subjects with advanced, metastatic or refractory solid tumors [ClinicalTrials.gov identifier NCT01585870]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov/ct2/show/NCT01585870. Accessed 29 Jan 2013.
50. Vahdat L, Schwartzberg L, Glück S, Rege J, Liao J, Cox D, et al. Results of a phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer [presentation P1-12-02]. In: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio.
51. Vahdat L, Schwartzberg L, Wilks S, Rege J, Liao J, Cox D, et al. Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a phase 2, multicenter, single-arm study [presentation P5-20-04]. In: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio.
52. Traina TA, Hudis C, Fornier M, Lake D, Lehman R, Berkowitz AP, et al. Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a phase 2, single-arm feasibility study [presentation P1-13-11]. In: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio.
53. Warsch S, Montero AJ, Glück S. Novel cytotoxic agents in the treatment of metastatic breast cancer. Curr Breast Cancer Rep. 2012;4:75-82. doi: 10.1007/s12609-011-0066-0.
54. Villanueva CB, Bazan FF, Pivot XB. New microtubule inhibitors in breast cancer. Curr Breast Cancer Rep. 2013;5:1-10. doi: 10.1007/s12609-012-0101-9.